Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Cultivated B
Heidelberg, Baden-Württemberg, Germany
- Ownership
- Private
- Employees
- ~70
- Development stage
- Other
01
Overview
The Cultivated B achieved a breakthrough with TCB-32, a small molecule mimicking bFGF, enabling more stable and cost-effective cell culture. Their AUXO V® bioreactor and biosensor systems are being piloted for scalable cultivated meat and other cellular agriculture products. Regulatory pre-submission for hybrid cultivated meat products in Europe has started.
- Therapeutic areas
- Other
- Modalities
- Cell therapySmall moleculeBiologicDeviceMicrobial therapy
- Industry
- Non-Drug Biotech
02
Partnerships
SiemensdenovoMATRIXThe Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain)Lambton College
Beyond the preview
Go deeper on The Cultivated B.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on The Cultivated B.